Cancer cachexia: It's time for more clinical trials

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 276-285

  Bossola, Maurizio ^a   Pacelli, Fabio ^a   Tortorelli, Antonio ^a   Doglietto, Giovan Battista ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anorexia; Approved therapy; Cancer cachexia; Candidate drugs; Muscle wasting

Indexed keywords

CANNABIS DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DRONABINOL; ETANERCEPT; FISH OIL; GHRELIN; HORMONE RECEPTOR BLOCKING AGENT; IBUPROFEN; ICOSAPENTAENOIC ACID; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 15; MEGESTROL ACETATE; MELANOCORTIN RECEPTOR ANTAGONIST; MELATONIN; MYOSTATIN; MYOSTATIN ANTIBODY; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NANDROLONE DECANOATE; OXANDROLONE; PENTOXIFYLLINE; PLACEBO; PROTEIN ANTIBODY; SURAMIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADRENAL INSUFFICIENCY; ALOPECIA; ANOREXIA; ARTICLE; BIOSYNTHESIS; BLOOD PRESSURE; CACHEXIA; CANCER; CANCER CACHEXIA; CANCER PATIENT; CATABOLISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COORDINATION DISORDER; DROWSINESS; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ENERGY EXPENDITURE; ENERGY METABOLISM; ENTERIC FEEDING; EXPERIMENTAL MODEL; FATIGUE; FLUID RETENTION; FUNCTIONAL DISEASE; HUMAN; HYPERGLYCEMIA; IMPOTENCE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUSCLE ATROPHY; NONHUMAN; NUTRITIONAL STATUS; PARANEOPLASTIC SYNDROME; PARENTERAL NUTRITION; PERIPHERAL EDEMA; PHENOTYPE; PHYSICAL ACTIVITY; PROTEIN DEGRADATION; PULSE PRESSURE; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKELETAL MUSCLE; THINKING IMPAIRMENT; THROMBOEMBOLISM; VOMITING; WEIGHT REDUCTION;

CACHEXIA; CLINICAL TRIALS; ENTERAL NUTRITION; HUMANS; NEOPLASMS; NUTRITIONAL STATUS; QUALITY OF LIFE;

EID: 33846593870     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9179-5     Document Type: Article

References (84)

1. Muscaritoli M, Bossola M, Aversa Z, et al. Prevention and treatment of cancer cachexia: new insights into and old problem. Eur J Cancer 2006; 42:31-41.
2. MacDonald N, Easson AM, Mazurak VC, et al. Understanding and managing cancer cachexia. J Am Coll Surg 2003; 197:143-161.
3. Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219:325-331.
4. Laviano A, Meguid MM, Rossi Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4:686-694.
5. Dempsey DT, Knox LS, Mullen JL, et al. Energy expenditure in malnourished patients with colorectal cancer. Arch Surg 1996; 121:789-795.
6. Gibney E, Elia M, Jebb SA, et al. Total energy expenditure in patients with non small-cell lung cancer: results of a validated study using the bicarbonate-urea method. Metabolism 1997; 46:1412-1417.
7. Jeevanandam M, Horowitz GD, Lowry SF, et al. Cancer cachexia and protein metabolism. Lancet 1984; 1:1423-1426.
8. Fearon KCH. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 1992; 51:251-265.
9. Tisdale MJ. The cancer cachectic factor. Support Care Cancer 2003; 11:73-78.
10. Todorov PT, Mc Devitt TM, Meyer DJ, et al. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 1998; 58:2353-2358.
11. Hirai K, Hussey HJ, Barber MD, et al. Biological evaluation of a lipid mobilizing factor isolated from the urine cancer patients. Cancer Res 1998; 58:2359-2365.
12. Khan S, Tisdale M. Catabolism of adipose tissue by a tumor-produced lipid mobilising factor. Int J Cancer 1999; 29:444-447.
13. Costelli P, Baccino FM. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care 2003; 6:407-412.
14. 2+-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer 2001; 84:946-950.
15. 2+-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine 2002; 19:1-5.
16. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1518-R1523.
17. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates whit disease severity in gastric cancer patients. Ann Surg 2003; 237:384-389.
18. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-1708.
19. Lecker SH, Jagoe T, Gilbert M, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in genes expression. FASEB J 2004; 18:39-51.
20. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-2366.
21. Costelli P, Muscaritoli M, Bossola M, et al. Skeletal muscle wasting in tumour-bearing rats is associated with MyoD down-regulation. Int J Oncol 2005; 26:1663-1668.
22. Kambadur R, Sharma M, Smith TP, Bass JJ. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997; 7:910-916.
23. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997; 94:12457-12461.
24. Szabo G, Dallmann G, Muller G, et al. A deletion in the myostatin gene causes the compact (Cmpt) hypermuscular mutation in mice. Mamm Genome 1998; 9:671-672.
25. Ma K, Mallidis C, Bhasin S, et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003; 285:E363-E371.
26. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002; 296:1486-1488.
27. McCroskery S, Thomas M, Maxwell L, et al. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 2003; 162:1135-1147.
28. Langley B, Thomas M, Bishop A, et al. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002; 277:49831-49840.
29. Gonzales-Cadavid NF, Bhasin S. Role of myostatin in metabolism. Curr Opin Clin Nutr Metab Care 2004; 7:451-457.
30. Lopez AP, Roque Figuls M, Cuchi GU, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Sympt Manag 2004; 27:360-369.
31. Klein TW, Lane B, Newton CA, et al. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000; 225:1-8.
32. Fide E, Bregman T, Kirkham TC, et al. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med 2005; 230:225-234.
33. Jatoi A, Windschiltl HE, Loprinzi CL, et al. Dronabinol versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment study. J Cin Oncol 2002; 20:567-573.
34. Baldwin C, Parsons T, Logan S. Dietary advice for illnessrelated malnutrition in adults. Cochrane Database Syst Rev 2001; 2:CD002008.
35. Milne AC, Potter J, Avenell A. Protein and energy supplementation in elderly people at risk of malnutrition. Cochrane database Syst Rev 2002; 3:CD003288.
36. Stratton RJ, Elia M. Are oral nutritional supplements of benefits in patients in the community? Findings from a systematic review. Curr Opin Clin Nutr Metab Care 2000; 3:311-315.
37. Bozzetti F. Rationale and indications for preoperative feeding of malnourished surgical cancer patients. Nutrition 2002; 18:953-959.
38. American Gastroenterological Association Medical position statement: parenteral nutrition. Gastroeneterology 2001; 121:966-969.
39. American Society for Parenteral and Enteral Nutrition Board of Directors Guidelines for the use of parenteral and enteral nutrition in adult pediatric patients. JPEN J Parenter Enteral Nutr 2002; 26:SA1-S138.
40. Arends J, Bodoky G, Bozzetti F, et al. ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006, May 11; Epub ahead of print.
41. Mirhosseini N, Fainsinger RL, Baracos V. Pareneteral nutrition in advanced cancer: indications and clinical practice guidelines. J Pall Med 2005; 8:914-918.
42. Lundholm K, Daneryd P, Bosaeus I, Komer Ulla, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function. Cancer 2004; 100:1967-1977.
43. Schattner M. Enteral nutritional support of the patient with cancer. J Clin Gastroenterol 2003; 36:297-302.
44. Bozzetti F, Gavazzi C, Mariani L, et al. Artificial nutrition in cancer patients: which route, what composition? World J Surg 1999; 23:577-583.
45. Mercadante S. Parenteral versus enteral nutrition in cancer patients: indications and practice. Support Care Cancer 1998; 6:85-93.
46. Whitehouse AS, Smith HJ, Drake JL, et al. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 2001; 61:3604-3609.
47. Wigmore SJ, Barber MD, Ross JA. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000; 36:177-184.
48. Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52:1479-1486.
49. Moses AWG, Slater C, Preston T, et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90:996-1002.
50. Jatoi A, Kendrith R, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both patients with cancer-associated wasting: a north central cancer treatment group and national cancer institute of Canada collaborative efforts. J Clin Oncol 2004; 22:2469-2476.
51. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005; 8:571-578.
52. Foster AC, Chen C, Markison S, Marks DL. MC4 receptor antagonists: a potential treatment for cachexia. IDrugs 2005; 8:314-319.
53. Markison S, Foster AC, Chen C, et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 2005; 146:2766-2773.
54. Nicholson JR, Kohler G, Schaerer F, et al. Peripheral administration of a melanocortin4-receptor inverse agonist prevents loss of a lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 2006, Jan 25; Epub ahead of print.
55. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Endocrinol Metab 2001; 86:5992-5995.
56. Druce MR, Neary NM, Small CJ, et al. Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. Int J Obes 2006; 30:293-296.
57. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrin Metab 2004; 89:2832-2836.
58. Combaret L, Ralliere C, Taillandier D, et al. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of the 20S and 26S proteasomes in muscles from tumour bearing rats. Mol Biol Rep 1999; 26:95-101.
59. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000; 60:273-292.
60. Lundholm K, Daneryd P, Korner U, et al. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 2004; 24:505-512.
61. Davis TW, Zweifel BS, O'Neal JM, et al. Inhibition of cyclooxygenase by celecoxib reverses tumour-2 induced wasting. J Pharmacol Exp Ther 2004; 308:929-934.
62. Muscaritoli M, Costelli P, Bossola M, et al. Effects of simvastatin administration in an experimental model of cancer cachexia. Nutrition 2003; 19:936-940.
63. Strassmann G, Fong M, Freter CE, et al. Suramin interfers with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 1993; 92:2152-2159.
64. Mori K, Fujimoto-Ouchi K, Ishikawa T, et al. Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 1996; 67:849-855.
65. Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 1995; 136:3669-3672.
66. Goldberg RM, Loprinzi CL, Maillard JA, et al. Pentoxiphylline for treatment of cancer anorexia and cachexia? A randomised, double-bind, placebo-controlled trial. J Clin Oncol 1995; 13:2856-2859.
67. Bruera E, Neumann CM, Pituskin E, Calder K, Ball G, Hanson J. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncology 1999; 10:857-859.
68. Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003; 17:677-683.
69. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54:540-545.
70. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336:186-195.
71. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in treatment of neoplastic cachexia?. Eur J Cancer 1996; 32:340-1343.
72. Pearson C, Glimelius B, Ronnelid J, et al. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomised pilot study. Nutrition 2005; 21:170-178.
73. Mc Millan DC, OGorman P, Fearon KC, et al. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J cancer 1997; 76:788-790.
74. Langer CJ, Hoffman JP, Ottery FD, et al. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition 2001; 17(Suppl):S1-S20.
75. Sheffield Moore M. Androgens and the control of skeletal muscle protein synthesis. Ann Med 2000; 32:181-186.
76. Demling RH, DeSanti L. Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns 2003; 29:793-797.
77. Earthman CP, Reid PM, Harper IT, et al. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN J Parenteral Enteral Nutr 2002; 26:357-365.
78. Creutzberg EC, Wouters EF, Mostert R, et al. A role for anabolic steroids in therehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 2003; 104:1733-1742.
79. Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986; 58:183-186.
80. Tchekmedyian S, Fesen M, Price LM, et al. Ongoing placebo-controlled study of oxandrolone in cancer-related weight loss. Int J Radiat Oncol Biol Phys 2003; 57(Suppl):S283-S284.
81. Bogdanovich S, Krag TOB, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420:418-421.
82. Wagner KR, McPherron AC, Winik N, et al. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002; 52:832-836.
83. Jatoi A, Jett JR, Sloan J, et al. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer 2004; 12:859-863.
84. Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor-alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006; 24:1852-1859.